AP3M2

Across TCGA pan-cancer cohorts, AP3M2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AP3M2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AP3M2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AP3M2 expression acts as an unfavorable survival marker.

HNSC, KICH, and BLCA are the cancer types where AP3M2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.086	0.751	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	OS	Median	III,IV	0.195	0.684	.010	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AP3M2–HNSC (OS)

Open the HNSC breakdown →